111 related articles for article (PubMed ID: 17519399)
1. Population pharmacokinetics of tigecycline in healthy volunteers.
Van Wart SA; Cirincione BB; Ludwig EA; Meagher AK; Korth-Bradley JM; Owen JS
J Clin Pharmacol; 2007 Jun; 47(6):727-37. PubMed ID: 17519399
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections.
Van Wart SA; Owen JS; Ludwig EA; Meagher AK; Korth-Bradley JM; Cirincione BB
Antimicrob Agents Chemother; 2006 Nov; 50(11):3701-7. PubMed ID: 16940069
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent.
Meagher AK; Ambrose PG; Grasela TH; Ellis-Grosse EJ
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):165-71. PubMed ID: 16105560
[TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetic and pharmacodynamic profile of tigecycline.
Meagher AK; Ambrose PG; Grasela TH; Ellis-Grosse EJ
Clin Infect Dis; 2005 Sep; 41 Suppl 5():S333-40. PubMed ID: 16080071
[TBL] [Abstract][Full Text] [Related]
5. Absence of an interaction between tigecycline and digoxin in healthy men.
Zimmerman JJ; Harper DM; Matschke K; Speth JL; Raible DG; Fruncillo RJ
Pharmacotherapy; 2007 Jun; 27(6):835-44. PubMed ID: 17542766
[TBL] [Abstract][Full Text] [Related]
6. Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects.
Hoffmann M; DeMaio W; Jordan RA; Talaat R; Harper D; Speth J; Scatina J
Drug Metab Dispos; 2007 Sep; 35(9):1543-53. PubMed ID: 17537869
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a potential tigecycline-warfarin drug interaction.
Zimmerman JJ; Raible DG; Harper DM; Matschke K; Speth JL
Pharmacotherapy; 2008 Jul; 28(7):895-905. PubMed ID: 18576904
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects.
Muralidharan G; Micalizzi M; Speth J; Raible D; Troy S
Antimicrob Agents Chemother; 2005 Jan; 49(1):220-9. PubMed ID: 15616299
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study.
Purdy J; Jouve S; Yan JL; Balter I; Dartois N; Cooper CA; Korth-Bradley J
Clin Ther; 2012 Feb; 34(2):496-507.e1. PubMed ID: 22249106
[TBL] [Abstract][Full Text] [Related]
10. Exposure-response analyses of tigecycline tolerability in healthy subjects.
Passarell J; Ludwig E; Liolios K; Meagher AK; Grasela TH; Babinchak T; Ellis-Grosse EJ
Diagn Microbiol Infect Dis; 2009 Oct; 65(2):123-9. PubMed ID: 19748422
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model.
Koomanachai P; Kim A; Nicolau DP
J Antimicrob Chemother; 2009 May; 63(5):982-7. PubMed ID: 19279050
[TBL] [Abstract][Full Text] [Related]
12. Tigecycline pharmacokinetics in subjects with various degrees of renal function.
Korth-Bradley JM; Troy SM; Matschke K; Muralidharan G; Fruncillo RJ; Speth JL; Raible DG
J Clin Pharmacol; 2012 Sep; 52(9):1379-87. PubMed ID: 21953572
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and safety of a single intravenous dose of the antibiotic tigecycline in patients with cirrhosis.
Korth-Bradley JM; Baird-Bellaire SJ; Patat AA; Troy SM; Böhmer GM; Gleiter CH; Buecheler R; Morgan MY
J Clin Pharmacol; 2011 Jan; 51(1):93-101. PubMed ID: 20308689
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.
Rubino CM; Ma L; Bhavnani SM; Korth-Bradley J; Speth J; Ellis-Grosse E; Rodvold KR; Ambrose PG; Drusano GL
Antimicrob Agents Chemother; 2007 Nov; 51(11):4085-9. PubMed ID: 17846139
[TBL] [Abstract][Full Text] [Related]
15. Establishing the role of tigecycline in an era of antimicrobial resistance.
Schafer JJ; Goff DA
Expert Rev Anti Infect Ther; 2008 Oct; 6(5):557-67. PubMed ID: 18847395
[TBL] [Abstract][Full Text] [Related]
16. Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints.
Ambrose PG; Meagher AK; Passarell JA; Van Wart SA; Cirincione BB; Rubino CM; Korth-Bradley JM; Babinchak T; Ellis-Grosse E
Diagn Microbiol Infect Dis; 2009 Jan; 63(1):38-42. PubMed ID: 19073300
[TBL] [Abstract][Full Text] [Related]
17. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose.
Rodvold KA; Gotfried MH; Cwik M; Korth-Bradley JM; Dukart G; Ellis-Grosse EJ
J Antimicrob Chemother; 2006 Dec; 58(6):1221-9. PubMed ID: 17012300
[TBL] [Abstract][Full Text] [Related]
18. A review of tigecycline--the first glycylcycline.
Peterson LR
Int J Antimicrob Agents; 2008 Dec; 32 Suppl 4():S215-22. PubMed ID: 19134522
[TBL] [Abstract][Full Text] [Related]
19. Penetration, efflux and intracellular activity of tigecycline in human polymorphonuclear neutrophils (PMNs).
Ong CT; Babalola CP; Nightingale CH; Nicolau DP
J Antimicrob Chemother; 2005 Sep; 56(3):498-501. PubMed ID: 16024591
[TBL] [Abstract][Full Text] [Related]
20. Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci.
Ambrose PG; Meagher AK; Passarell JA; Van Wart SA; Cirincione BB; Bhavnani SM; Ellis-Grosse E
Diagn Microbiol Infect Dis; 2009 Feb; 63(2):155-9. PubMed ID: 19150707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
